别名 CD119、CDw119、IFN-gamma receptor 1 + [6] |
简介 Receptor subunit for interferon gamma/INFG that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation (PubMed:20015550). Associates with transmembrane accessory factor IFNGR2 to form a functional receptor (PubMed:7615558, PubMed:2971451, PubMed:7617032, PubMed:10986460, PubMed:7673114). Upon ligand binding, the intracellular domain of IFNGR1 opens out to allow association of downstream signaling components JAK1 and JAK2. In turn, activated JAK1 phosphorylates IFNGR1 to form a docking site for STAT1. Subsequent phosphorylation of STAT1 leads to dimerization, translocation to the nucleus, and stimulation of target gene transcription (PubMed:28883123). STAT3 can also be activated in a similar manner although activation seems weaker. IFNGR1 intracellular domain phosphorylation also provides a docking site for SOCS1 that regulates the JAK-STAT pathway by competing with STAT1 binding to IFNGR1 (By similarity). |
靶点 |
作用机制 IFNγR1激动剂 |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期1990-12-20 |
靶点 |
作用机制 IFNγR1激动剂 |
在研机构- |
在研适应症- |
非在研适应症 |
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 IFNγR1激动剂 |
在研机构- |
原研机构 |
在研适应症- |
非在研适应症 |
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-01-01 |
开始日期2022-03-31 |
开始日期2017-12-15 |